Strengthening the academic dermatology workforce is an issue that faces challenges in both recruitment and retention of dermatologists. 1 There has been considerable interest in identifying factors associated with dermatology trainees' entry into academics. 2, 3 As research productivity and publications represent key elements in academia, these components may help assess trainees' potential to pursue academic dermatology. We examined associations between demographic, academic, and publication factors and dermatology trainees' initial choice of academic vs private practice careers. Table 2 ). The study cohort had a mean of 2.6 PRPs (range, 0-26), including a mean of 1.7 dermatologyspecific PRPs (range, 0-24). Individuals with PhDs had significantly more total PRPs than those without PhDs (7.1 vs 1.7; P < .001), but there was no significant difference between these 2 groups in dermatology-specific PRPs. The mean number of in-residency publications was 2.95 (range, 0-35), with no significant difference between individuals with and without PhDs.
Individuals with 2 or more PRPs were significantly more likely than those with 1 PRP or fewer to pursue an academic career (OR, 1.95; 95% CI, 1.28-2.98; P = .002). Individuals with 4 dermatology-specific PRPs or more were significantly more likely than individuals with 3 dermatology-specific PRPs or fewer to choose academics (OR, 1.84; 95% CI, 1.03-3.29; P = .04). Finally, having 4 in-residency publications or more was statistically associated with academic career choice (OR, 1.61; 95% CI, 1.03-2.51; P = .04).
Discussion | This study represents the first nationwide analysis of factors associated with dermatology trainees' entrance into academic dermatology careers. Preresidency publications represent a significant factor in the residency selection process for dermatology trainees 4 ; our analysis suggests that PRPs may be indicative of trainees' interest in academic practice. Our findings regarding the association between preresidency and in-residency academic productivity and pursuit of academic careers are consistent with trends observed in several other specialties. 5, 6 Causes of this observed association warrant further investigation, but are likely multifactorial and may include trainees' access to mentorship and skills training pertinent to academia such as study design and writing manuscripts. Overall, this study offers insights for identifying and encouraging trainee entry into academic dermatology.
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OBSERVATION Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae
Immune checkpoint inhibitor therapies targeting PD-1 or CTLA-4 (programmed cell death 1 or cytotoxic T-lymphocyte-associated 4 protein) are increasingly used to treat metastatic melanoma. 1 The most common adverse event from these classes of drugs is cutaneous toxic effects. 1,2 The mechanism is incompletely understood but thought to be mediated by CD4-positive and CD8-positive T cells activated by immunotherapy. 3 Immunotherapyinduced cutaneous eruptions include discrete or generalized papules without regional preference or, rarely, in inverse distribution. We report 2 cases of patients with metastatic melanoma who developed spongiotic cutaneous eruptions limited to the region of their melanoma locoregional metastases.
Report of Cases | Case 1. A woman in her 80s was diagnosed with nodular melanoma of the left great toe (Breslow depth, 8 mm; stage IIC). Two years after partial amputation and negative findings on sentinel lymph node biopsy, she developed in-transit metastases to the left anterior shin and medial thigh and regional metastases to the left inguinal lymph nodes. Six months after excision of the in-transit metastases and inguinal node dissection, multiple additional in-transit metastases and suspect lung and mediastinal masses were found. Treatment with ipilimumab, 3 mg/kg every 3 weeks (4 cycles), was initiated and then switched to dabrafenib and trametinib after she developed additional in-transit metastases. After 2 months the disease had progressed, and so therapy was changed to pembrolizumab, 2 mg/kg every 3 weeks. After 1 month (2 cycles), she developed an asymptomatic scaly pink plaque in the left groin. The eruption progressed but was limited to her left anterior thigh extending to the left knee and encompassing the anatomic region of her recurrent in-transit metastases (Figure 1) . Punch biopsy findings showed spongiotic dermatitis with eosinophils. The eruption resolved after application of clobetasol ointment without discontinuation of pembrolizumab therapy. At last follow-up, she had completed 26 cycles of pembrolizumab treatment with complete resolution of in-transit metastases and a few residual, small, nonspecific lung nodules seen on positron emission tomography-computed tomography images.
Case 2.
A man in his 50s presented with a suprapubic midline melanoma and regional metastases to bilateral inguinal lymph nodes (Breslow depth, 10 mm; stage IIIC). He underwent wide local excision, bilateral inguinal lymph node dissection, and subsequently began ipilimumab therapy, 3 mg/kg every 3 weeks. One month later, he developed pruritic, pink, scaly plaques with honey-colored crust on the bilateral upper thighs and koebnerized within the left inguinal surgical scar ( Figure 2) . Shave biopsy results showed spongiotic dermatitis with eosinophils. The impetiginized eruption resolved after treatment with oral cephalexin and a mix of clobetasol and mupirocin ointments. Ipilimumab therapy was stopped owing to severe grade 2 to 3 colitis. Eight months later, he developed brain metastases and was treated with resection and initiation of pembrolizumab therapy. At last follow-up, after 15 cycles of pembrolizumab, he was largely disease free and without any cutaneous adverse effects. Pink, scaly plaque is limited to the left thigh and knee in the area of in-transit metastases.
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